Marinomed Biotech AG (WBAG: MARI)
Health Care · Pharmaceuticals · AT
€4.50
-10.00% today · -74.9% 1Y
Marinomed Biotech AG (WBAG: MARI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $11.67M and employs 32 people.
Over the last twelve months the share price has lost 74.9%, trading between 2.20 and 21.00.
Tweenvest scores Marinomed Biotech AG across four factors: quality 16/100, value 61/100, growth 52/100. Its strongest factor is value.
MARI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $11.67M
- Revenue (TTM)
- $9.35M
- P/E
- 0.51
- EPS
- 9.79
- Dividend yield
- —
- Beta (5Y)
- -0.23
- 52-week high
- €21.00
- 52-week low
- €2.20
- Avg volume (3M)
- —
- Shares outstanding
- 2.00M
- Employees
- 32
- Next earnings
- —
About Marinomed Biotech AG
Marinomed Biotech AG is an Austrian-based biopharmaceutical firm dedicated to developing therapeutic solutions for viral and immunological conditions, with its market presence spanning across Austria, other European nations, and globally. Their comprehensive product pipeline includes Budesolv, which addresses allergic rhinitis and autoimmune gastritis, and Tacrosolv, currently undergoing Phase II clinical trials for anterior inflammatory eye diseases. Also featured in their development are Carravin, designed to alleviate nasal congestion, and Inhaleen, which is in Phase I clinical evaluation for viral pneumonia. Additionally, the company offers Carragelose, a range of products like nasal and throat sprays and lozenges, all formulated to combat viral respiratory infections. Established in 2006, the company was initially named Marinomed Biotechnologie GmbH, adopting its current name, Marinomed Biotech AG, in June 2017, and is headquartered in Korneuburg, Austria.
- ISIN
- ATMARINOMED6
- Founded
- 2006
- Listed since
- Feb 1, 2019
- Exchange
- Wiener Boerse AG
- Currency
- EUR
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.10T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $658.24B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $385.99B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $371.62B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $303.81B | CHF128.34 | +1.25% |
| AstraZeneca PLCLSE: AZN | $263.84B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $212.51B | Dkr307.80 | +2.86% |
| Pfizer Inc.NYSE: PFE | $162.84B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.